 ATLANTA, Jan. 05, 2023 GLOBE NEWSWIRE Virios Therapeutics, Inc. Nasdaq: VIRI, a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia FM, announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration FDA to discuss advancing IMC-1 into Phase 3 development ... The post Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 t... 